Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
November 18, 2003
ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat
Ruolun Qiu, Thomas F Kalhorn, John T Slattery
Clinical Pharmacology in Drug Development
|
September 1, 2022
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
Jim H Hughes, Ruolun Qiu, Christopher Banfield, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 12, 2025
Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection
Yeamin Huh, Ruolun Qiu, John Prybylski, et al.
The American Journal of Psychiatry
|
April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
Brendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 3, 2024
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, et al.
Journal of Clinical Psychopharmacology
|
December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder
Arthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Pharmaceutical Research
|
April 14, 2016
Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example
Marci L Chew, Joyce Mordenti, Thean Yeoh, et al.
British Journal of Clinical Pharmacology
|
May 15, 2023
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a <sup>14</sup> C-microdose approach
Ruolun Qiu, Raman Sharma, Hua Wei, et al.
Diabetes, Obesity & Metabolism
|
December 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, et al.
Clinical Pharmacology and Therapeutics
|
September 17, 2004
Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard
Ruolun Qiu, Amy Yao, Paolo Vicini, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
The Journal of Pharmacology and Experimental Therapeutics
|
November 18, 2003
ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat
Ruolun Qiu, Thomas F Kalhorn, John T Slattery
Clinical Pharmacology in Drug Development
|
September 1, 2022
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
Jim H Hughes, Ruolun Qiu, Christopher Banfield, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 12, 2025
Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection
Yeamin Huh, Ruolun Qiu, John Prybylski, et al.
The American Journal of Psychiatry
|
April 17, 2008
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression
Brendon Binneman, Douglas Feltner, Sheela Kolluri, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 3, 2024
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, et al.
Journal of Clinical Psychopharmacology
|
December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder
Arthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Pharmaceutical Research
|
April 14, 2016
Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example
Marci L Chew, Joyce Mordenti, Thean Yeoh, et al.
British Journal of Clinical Pharmacology
|
May 15, 2023
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a <sup>14</sup> C-microdose approach
Ruolun Qiu, Raman Sharma, Hua Wei, et al.
Diabetes, Obesity & Metabolism
|
December 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, et al.
Clinical Pharmacology and Therapeutics
|
September 17, 2004
Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard
Ruolun Qiu, Amy Yao, Paolo Vicini, et al.
Page
of 3